Amrad halts buyback during Avexa spin-out

By Melissa Trudinger
Thursday, 01 July, 2004

Amrad (ASX:AML) has halted its share buy-back program while it readies itself to spin out its anti-infectives program.

The process will allow the company to calculate the entitlements of shareholders so that shares can be distributed into the new company, Avexa, during the demerger. Amrad shareholders will receive shares in Avexa on a pro rata basis according to their holdings in Amrad on the record date for the offer.

The Amrad share buy-back program will continue once the record date has passed, the company said.

Related News

Abnormal brain protein targeted in Parkinson's study

Researchers have identified a new brain protein involved in the development of Parkinson's...

Epilepsy disease model treated in a laboratory dish

A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...

Newborns have elevated levels of an Alzheimer's biomarker

What do the brains of newborns and patients with Alzheimer's disease have in common? Both...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd